远大医药(00512)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00512 远大医药

收市竞价 08-19 16:02:13

5.255

-0.140

-2.59%

最高5.400	最低5.220	成交量364.40万
今开5.400	昨收5.395	日振幅3.34%
总市值186.55亿	流通市值186.53亿	总股本35.50亿
成交额1,918万	换手率0.10%	流通股本35.50亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00512","market":"HK","secType":"STK","nameCN":"远大医药","latestPrice":5.255,"timestamp":1787126511789,"preClose":5.395,"halted":0,"volume":3644000,"delay":0,"changeRate":-0.025949953660796977,"floatShares":3549571148,"shares":3550000000,"eps":0.3544,"marketStatus":"收市竞价","change":-0.14,"latestTime":"08-19 16:02:13","open":5.4,"high":5.4,"low":5.22,"amount":19181427,"amplitude":0.033364,"askPrice":5.255,"askSize":49500,"bidPrice":5.255,"bidSize":51500,"shortable":3,"etf":0,"ttmEps":0.3544,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1787127000000},"marketStatusCode":4,"adr":0,"listingDate":819302400000,"exchange":"SEHK","adjPreClose":5.395,"dividendRate":0.03216,"openAndCloseTimeList":[[1787103000000,1787112000000],[1787115600000,1787126400000]],"volumeRatio":0.679649,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00512","defaultTab":"news","newsList":[{"id":"1170552830","title":"远大医药（00512）将于8月26日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1170552830","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170552830?lang=zh_cn&edition=full","pubTime":"2026-08-10 17:05","pubTimestamp":1786352739,"startTime":"0","endTime":"0","summary":"远大医药（00512）8月10日晚间公告称，公司董事会会议将于2026年8月26日（星期三）举行，主要议程包括审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩，以及处理其他相关事项（如有）。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658660609","title":"港股异动 | 远大医药(00512)早盘涨超5% 自研GPN01530-2斩获美国FDA快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2658660609","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658660609?lang=zh_cn&edition=full","pubTime":"2026-08-10 09:44","pubTimestamp":1786326245,"startTime":"0","endTime":"0","summary":"消息面上，8月9日，远大医药发布公告，集团自主研发的用于诊断实体瘤的全球创新放射性核素偶联药物  GPN01530-2近日获得美国食品药品监督管理局授予的快速通道资格。FDA 设立快速通道机制，旨在加速和促进用于治疗当前并无有效治疗方案的严重或危及生命的疾病、且展示出有满足这一疾病当前未被满足的医疗需求潜力的新药的评审过程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477795.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","00512","BK1191","LABU","KCAI","VXUS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658672042","title":"国产FAP核药获美国FDA加速审批通道 远大医药依托一体化核药产业链角逐核药市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2658672042","media":"证券日报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658672042?lang=zh_cn&edition=full","pubTime":"2026-08-09 19:54","pubTimestamp":1786276440,"startTime":"0","endTime":"0","summary":"远大医药集团有限公司（以下简称“远大医药”）发布公告称，公司FAP靶点创新核药GPN01530-2已获得美国FDA授予快速通道资格（FastTrackDesignation，FTD）。FTD资格主要授予用于治疗严重疾病且有潜力解决未满足医疗需求的在研药物，旨在加速高价值在研药物的审评进程。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608093835965072.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608093835965072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","00512","LABU","BK1191","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658728656","title":"中国FAP靶向实体瘤诊断核药首次获FDA快速通道资格认定，远大医药(00512)自研产品直击泛实体瘤千亿美元未满足市场需求","url":"https://stock-news.laohu8.com/highlight/detail?id=2658728656","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658728656?lang=zh_cn&edition=full","pubTime":"2026-08-09 18:18","pubTimestamp":1786270729,"startTime":"0","endTime":"0","summary":"作为核药龙头企业，远大医药近日在该领域再次取得重磅突破，公司FAP靶点创新核药GPN01530-2已获得美国FDA授予快速通道资格，成为全球首个获得FDA快速通道认定的实体瘤FAP靶点诊断核药。据悉，GPN01530-2此前已获FDA批准开展用于诊断实体瘤的I/II期临床研究，此次其获快速通道资格认定，标志着美国监管机构认可该产品在实体瘤诊断的重要潜力，有望加快GPN01530-2未来开发及上市进程，尽早惠及全球患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477702.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK4588","00512","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114475235","title":"远大医药：自主研发全球创新放射性核素偶联药物GPN01530-2获FDA快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1114475235","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114475235?lang=zh_cn&edition=full","pubTime":"2026-08-09 18:12","pubTimestamp":1786270330,"startTime":"0","endTime":"0","summary":"远大医药近日宣布，其独立自主研发、具备全球创新性的放射性核素偶联药物——GPN01530-2，已获得美国食品药品监督管理局授予的快速通道资格。GPN01530-2作为一款前沿的放射性核素靶向治疗药物，其设计旨在精准递送辐射剂量至肿瘤细胞，同时最大限度地减少对健康组织的损伤。远大医药在核药领域的持续深耕，正逐步构建起涵盖研发、生产及商业化的完整产业链，而此次GPN01530-2的突破，无疑进一步巩固了其在全球创新药竞争格局中的位置。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109236483","title":"远大医药（00512）自主研发放射性核素偶联药物GPN01530-2获FDA快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1109236483","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109236483?lang=zh_cn&edition=full","pubTime":"2026-08-09 18:11","pubTimestamp":1786270277,"startTime":"0","endTime":"0","summary":"8月9日，远大医药公告，其自主研发的靶向成纤维细胞活化蛋白小分子放射性核素偶联药物GPN01530-2已获美国食品药品监督管理局授予快速通道资格。此前，GPN01530-2已获FDA批准开展用于诊断实体瘤的I/II期临床研究。公告显示，GPN01530-2通过特异性靶向FAP，为多种恶性实体瘤的诊断提供新方案。远大医药提醒，GPN01530-2处于研发阶段，能否最终获批上市并实现商业化存在不确定性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658723636","title":"远大医药：自主研发放射性核素药物GPN01530-2获FDA快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2658723636","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658723636?lang=zh_cn&edition=full","pubTime":"2026-08-09 18:07","pubTimestamp":1786270020,"startTime":"0","endTime":"0","summary":"南财智讯8月9日电，远大医药（00512.HK）发布自愿公告，公司自主研发的全球创新放射性核素偶联药物GPN01530-2近日获得美国食品药品监督管理局（FDA）授予的快速通道资格（FastTrackDesignation），用于诊断实体瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608093835946655.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608093835946655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LABU","BK1191","BK4585","BK4588","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132632271","title":"远大医药2026年7月股份变动月报表：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1132632271","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132632271?lang=zh_cn&edition=full","pubTime":"2026-08-03 17:33","pubTimestamp":1785749629,"startTime":"0","endTime":"0","summary":"远大医药集团有限公司（股票代码：00512）于2026年8月3日披露截至2026年7月31日的证券变动月报表。公告显示，公司本月法定股本总额保持在港币10亿元（1000,000,000），对应的注册股本为1000亿股，面值为每股港币0.01，较上月底未发生变化。\n已发行股份方面，远大医药集团有限公司于报告期内总计拥有3,549,571,148股股份，库藏股数量维持为零，已发行股份总数与上月持平，未有新增发行、回购或注销股份的情形，也不存在与期权、权证及可换股债券相关的变动。公司表示将继续遵守香港联合交易所有限公司证券上市规则及相关法律法规，公告由公司秘书傅天忠签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113347739","title":"远大医药（00512）公告自2026年8月3日起变更百慕大注册及股份过户登记处地址","url":"https://stock-news.laohu8.com/highlight/detail?id=1113347739","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113347739?lang=zh_cn&edition=full","pubTime":"2026-07-31 17:06","pubTimestamp":1785488764,"startTime":"0","endTime":"0","summary":"远大医药集团有限公司（股票代码：00512）7月31日在港交所公告称，公司位于百慕大的主要股份过户登记处及注册办事处地址将自2026年8月3日（星期一）起变更为：Richmond House, 12 Par-la-Ville Road, Hamilton HM 08, Bermuda。\n公告显示，截至公告日，公司董事会由以下人员组成：执行董事唐纬坤博士、周超先生、杨光先生及林芷伊女士；独立非执行董事苏彩云女士、邢丽娜博士、裴更博士及胡野碧先生。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653757741","title":"远大医药：抑郁症中药创新药GPN01360III期临床完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2653757741","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653757741?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:50","pubTimestamp":1784803800,"startTime":"0","endTime":"0","summary":"7月23日，远大医药（00512）发布公告，公司用于治疗抑郁症的中药创新药GPN01360在中国开展的III期临床研究完成了首例患者入组给药。该研究计划入组480例抑郁症患者，口服给药8周，旨在评估GPN01360相较于安慰剂治疗抑郁症的有效性、安全性和耐受性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607233819076010.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607233819076010.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","IBBQ","00512","BK1191","159992","BK1574","06978","MEDX","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653483749","title":"远大医药(00512.HK)掘金百亿中药治疗抑郁症创新赛道 GPN01360国内III期临床完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2653483749","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653483749?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:35","pubTimestamp":1784802907,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653746799","title":"远大医药(00512.HK)：中药1.1类创新药GPN01360在中国开展的III期临床研究完成首例患者入组给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2653746799","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653746799?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:20","pubTimestamp":1784802025,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06978","BK1574","00512","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135948158","title":"远大医药创新中药GPN01360在华III期临床完成首例给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1135948158","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135948158?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:16","pubTimestamp":1784801787,"startTime":"0","endTime":"0","summary":"2026年7月23日，远大医药集团有限公司发布自愿公告称，其用于治疗抑郁症的1.1类中药创新药GPN01360已在中国III期临床研究中完成首例患者入组并给药。该项目被列入国家“重大新药创制”专项。据公告，III期研究为随机、双盲、安慰剂平行对照、多中心设计，计划入组480例抑郁症患者，口服给药8周。GPN01360源自古代方剂“逍遥散”，处方由柴胡、郁金、佛手等12味中药组成，具有疏肝健脾、解郁安神功效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649617239","title":"港股异动 | 远大医药(00512)涨超4% 合作伙伴全球首创核药TLX591-Tx再传佳音 临床数据获得验证","url":"https://stock-news.laohu8.com/highlight/detail?id=2649617239","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649617239?lang=zh_cn&edition=full","pubTime":"2026-07-06 10:16","pubTimestamp":1783304170,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，远大医药涨超4%，截至发稿，涨3.5%，报5.33港元，成交额759.19万港元。此前，在2026年ASCO年会上公布的ProstACT Global第一部分主要研究结果显示，TLX591-Tx联合标准疗法安全性、耐受性良好，血液学事件短暂可控，关键器官辐射暴露安全，药物肿瘤滞留性优异且无明显药物间相互作用。同时，与其他PSMA靶向小分子放射性配体疗法相比，TLX591-Tx治疗展现出了不同的靶向性和药理学特性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1463345.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","VXUS","KCAI","00512","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648133653","title":"远大医药(00512.HK)合作伙伴全球首创核药TLX591-Tx再传佳音 核药龙头带来前列腺癌治疗新希望","url":"https://stock-news.laohu8.com/highlight/detail?id=2648133653","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648133653?lang=zh_cn&edition=full","pubTime":"2026-07-03 13:10","pubTimestamp":1783055459,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["00512","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648065318","title":"远大医药(00512)合作伙伴全球首创核药TLX591-Tx再传佳音 核药龙头带来前列腺癌治疗新希望","url":"https://stock-news.laohu8.com/highlight/detail?id=2648065318","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648065318?lang=zh_cn&edition=full","pubTime":"2026-07-03 13:10","pubTimestamp":1783055459,"startTime":"0","endTime":"0","summary":"随着TLX591-Tx全球临床的持续推进，有望全球前列腺癌患者提供全新的精准治疗选择。预计2030年，全球前列腺癌药物市场将增至345亿美元，复合年增长率约10.5%。管线矩阵多点开花，持续深化全链条核药发展体系TLX591-Tx此次披露的积极临床数据，印证了放射性核素药物治疗前列腺癌的临床价值，也凸显出远大医药锚定核药赛道布局的前瞻性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462786.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0187","BK0012","000876","BK0188","00512","BK0238","BK0028","BK0183","BK0196","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192642271","title":"远大医药6月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1192642271","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192642271?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:22","pubTimestamp":1782984166,"startTime":"0","endTime":"0","summary":"7月2日，远大医药发布截至2026年6月30日的股份变动月报表。公告显示，公司本月无新增发行、回购或注销股份，股本整体维持不变。已发行股本及库存股方面，与上月一致，已发行普通股股份数目为3,549,571,148股，库存股份数目为0股，合计3,549,571,148股。截至6月末，远大医药股本总数保持稳定，未有新增发行及回购活动。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197835522","title":"远大医药与华东医药等达成协议 将供应药品制剂及原料等","url":"https://stock-news.laohu8.com/highlight/detail?id=1197835522","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197835522?lang=zh_cn&edition=full","pubTime":"2026-06-08 17:07","pubTimestamp":1780909621,"startTime":"0","endTime":"0","summary":"根据一项新达成的协议，远大医药（中国）有限公司将向华东医药股份有限公司及其他相关方供应药品制剂、原料药及其他相关产品。\n此项合作旨在整合双方在医药领域的资源与优势，通过稳定的供应链安排，保障相关药品及原料的及时供应。协议的履行预计将对双方的业务发展产生积极影响。\n远大医药作为供应方，其产品线覆盖范围及生产能力是此项合作的基础。而华东医药等作为接收方，其市场渠道与分销网络将有助于相关产品的后续推广与销售。此次合作展现了医药企业间强化产业协同、优化资源配置的市场趋势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641175999","title":"远大医药(00512)核药合作伙伴重磅产品亮相ASCO 全球首创RDC药物硬核数据夯实全球竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2641175999","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2641175999?lang=zh_cn&edition=full","pubTime":"2026-06-07 18:09","pubTimestamp":1780826974,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，近日，远大医药核药领域的重要战略合作伙伴Telix Pharmaceuticals Limited 全球创新产品TLX591-Tx重磅亮相2026 ASCO年会，其治疗转移性去势抵抗性前列腺癌的全球III期临床试验的第一部分试验数据完成首次大会口头汇报，展现了该产品优异的临床安全性以及药代动力学特征，充分验证了该产品的临床潜力，未来或将为mCRPC精准治疗再添全新利器。WHO国际癌症研究机构发布的最新数据显示，2022年全球前列腺癌新发病例146.8万，死亡人数近40万。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451124.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","RDC","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126045583","title":"远大医药5月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1126045583","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126045583?lang=zh_cn&edition=full","pubTime":"2026-06-03 18:41","pubTimestamp":1780483317,"startTime":"0","endTime":"0","summary":"远大医药集团有限公司于2026年6月3日发布本公司截至2026年5月31日的股份变动月报表。报告显示，远大医药在此期间未进行新增发行、购回、注销或库藏股活动，股本保持稳定。根据公告，截至5月末，公司法定及注册股本维持为100,000,000,000股普通股，面值每股港币0.01元，相当于法定/注册股本总额港币10亿元。本次公告由公司秘书傅天忠签署。根据月报信息，截至5月31日，公司股本总数保持不变，未有股份发行及回购活动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.chinagrandpharm.com","stockEarnings":[{"period":"1week","weight":0.0257},{"period":"1month","weight":0.0455},{"period":"3month","weight":0.0004},{"period":"6month","weight":-0.2607},{"period":"1year","weight":-0.334},{"period":"ytd","weight":-0.2889}],"compareEarnings":[{"period":"1week","weight":-0.0071},{"period":"1month","weight":0.037},{"period":"3month","weight":-0.007},{"period":"6month","weight":-0.0462},{"period":"1year","weight":0.0117},{"period":"ytd","weight":-0.0062}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"远大医药集团有限公司是一家主要从事医药业务的投资控股公司。该公司主要从事制造及销售医药制剂及医疗器械。该公司还从事制造及销售生物技术产品、健康产品、精品原料药和其他产品。该公司的主要产品包括核药抗肿瘤诊疗及心脑血管介入诊疗科技产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.451613,"avgChangeRate":0.084145},{"month":2,"riseRate":0.709677,"avgChangeRate":0.104891},{"month":3,"riseRate":0.387097,"avgChangeRate":0.015748},{"month":4,"riseRate":0.612903,"avgChangeRate":0.013455},{"month":5,"riseRate":0.451613,"avgChangeRate":0.076266},{"month":6,"riseRate":0.354839,"avgChangeRate":-0.048729},{"month":7,"riseRate":0.387097,"avgChangeRate":-0.011524},{"month":8,"riseRate":0.419355,"avgChangeRate":0.007847},{"month":9,"riseRate":0.466667,"avgChangeRate":-0.03929},{"month":10,"riseRate":0.5,"avgChangeRate":-0.014639},{"month":11,"riseRate":0.5,"avgChangeRate":0.085072},{"month":12,"riseRate":0.5,"avgChangeRate":-0.007406}],"exchange":"SEHK","name":"远大医药","nameEN":"GRAND PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"远大医药(00512)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供远大医药(00512)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"远大医药,00512,远大医药股票,远大医药股票老虎,远大医药股票老虎国际,远大医药行情,远大医药股票行情,远大医药股价,远大医药股市,远大医药股票价格,远大医药股票交易,远大医药股票购买,远大医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"远大医药(00512)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供远大医药(00512)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}